FDA approves Novartis drug Cosentyx to treat hidradenitis suppurativa patients
Phase III data showed Cosentyx can provide rapid relief from symptoms of hidradenitis suppurativa as early as Week 2
The US Food and Drug Administration...
Engage with Experts: Connect with industry leaders, renowned pharmacists, and forward-thinking researchers through exclusive live Q&A sessions and engaging discussions. Tap into their wisdom, ask burning questions, and gain invaluable insights to fuel your passion for pharmacy
Copyright © 2023 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc